Thoracic malignancies, cisplatin and renal function

Nortier J., Sculier J-P.

Source: Eur Respir J 2011; 37: 760-761
Journal Issue: April

Full text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Nortier J., Sculier J-P.. Thoracic malignancies, cisplatin and renal function. Eur Respir J 2011; 37: 760-761

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Does consolidation chemotherapy improves survival for locally advanced non-small-cell lung cancer patients receiving concurrent chemoradiotherapy?
Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up
Year: 2016


Poor prognostic factors in advanced pulmonary adenocarcinoma patients receiving first-line gefitinib
Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life
Year: 2013

The prognostic significance of thrombocytopenia during chemotherapy in patients with advanced non-small cell lung cancer
Source: International Congress 2016 – Basic science and case reports in lung cancer
Year: 2016

Electrospray-mediated local chemotherapy of lung carcinoma in mice
Source: International Congress 2016 – Basic science and case reports in lung cancer
Year: 2016

Ifosfamide (IFO) is a valuable alternative to cisplatin (CDDP) for first-line chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC): A meta-analysis
Source: Annual Congress 2013 –Advances in the therapy of lung cancer
Year: 2013

The effect of everolimus on lung function and renal status in lung transplanted patients
Source: International Congress 2016 – Post-transplant complications: from animal models to the bedside
Year: 2016

Influence of neoadjuvant therapy to complication rate after surgery for primary lung cancer
Source: International Congress 2016 – Surgical strategy for complex diseases
Year: 2016

Contribution of adjuvant chemotherapy in stage I pulmonary adenocarcinoma after surgical resection
Source: International Congress 2016 – Surgical strategy for complex diseases
Year: 2016

Impact of second-line treatment on overall survival of advanced lung adenocarcinoma patients
Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up
Year: 2016

Accelereated hyperfractionated radiotherapy with uneven crushing daily dose in chemoradiation treatment of inoperable non-small cell lung cancer
Source: International Congress 2015 – Lung cancer therapy: clinical trials
Year: 2015


Metronomic chemotherapy in human lung cancer: Mathematical modeling for an optimal schedule
Source: International Congress 2015 – Lung cancer therapy: clinical trials
Year: 2015


Gefitinib versus erlotinib as first-line treatment in EGFR mutant advanced lung adenocarcinoma
Source: International Congress 2016 – Therapeutic trials in lung cancer
Year: 2016


Carboplatin and paclitaxel chemotherapy for lung cancer patients with interstitial lung disease
Source: Annual Congress 2010 - Treatment of lung cancer
Year: 2010

Locoregional recurrence after pulmonary segmentectomy of non-small cell lung cancer
Source: Annual Congress 2013 –Oncological thoracic surgery
Year: 2013


Acute lung injury associated with 5-fluorouracil and oxaliplatinum combined chemotherapy
Source: Eur Respir J 2001; 18: 243-245
Year: 2001



Pulmonary function changes after chemotherapy and radiotherapy for Lymphoma.
Source: International Congress 2017 – Case reports and series
Year: 2017

Checkpointinhibition in lung cancer – How to distinguish pseudoprogression from progressive disease
Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up
Year: 2016


Malignant tumours in lung transplant recipients
Source: International Congress 2016 – Long-term outcomes of lung transplantation
Year: 2016

Lung adenocarcinoma mimicking interstitial lung disease showed good response to navelbine monotherapy
Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up
Year: 2016


Possible indication for surgical resection of lung cancer associated with combined pulmonary fibrosis and emphysema (CPFE)
Source: Annual Congress 2013 –Diffuse pulmonary fibrosis
Year: 2013